Lantus

DRUG12 trials

Conditions

DiabetesDiabetes MellitusDiabetes Mellitus Type IIDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic RetinopathyHealthyHealthy Volunteers

Early Phase 1

Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens

NCT02587741

Third Affiliated Hospital, Sun Yat-Sen UniversityDiabetic Retinopathy

Start: 2015-07-31End: 2025-07-31Target: 600Updated: 2015-10-27

Phase 1

A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects

CompletedNCT01374178

Eli Lilly and CompanyDiabetes Mellitus

Start: 2011-06-30End: 2011-07-31Updated: 2014-10-07

A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants

CompletedNCT01476345

Eli Lilly and CompanyDiabetes Mellitus

Start: 2011-11-30End: 2012-07-31Updated: 2014-10-07

A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus

CompletedNCT01600950

Eli Lilly and CompanyDiabetes Mellitus, Type 1

Start: 2012-05-31End: 2012-07-31Updated: 2014-10-07

A Study of LY2963016 in Healthy Participants

CompletedNCT01634165

Eli Lilly and CompanyHealthy Volunteers

Start: 2012-07-31End: 2012-09-30Updated: 2014-10-07

A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

CompletedNCT02514850

AdociaType 2 Diabetes Mellitus

Start: 2015-07-31End: 2015-11-30Updated: 2015-12-02

A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants

CompletedNCT03555305

Eli Lilly and CompanyHealthy

Start: 2018-09-26End: 2019-11-04Updated: 2020-11-24

Phase 2

Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

TerminatedNCT00767000

Merck Sharp & Dohme LLCDiabetes Mellitus, Type 2

Start: 2008-10-31End: 2010-06-30Updated: 2015-02-19

Phase 3

LANN-study: Lantus, Amaryl, Novorapid, Novomix Study

CompletedNCT00151697

Rijnstate HospitalDiabetes Mellitus Type II

Start: 2005-05-31Target: 150Updated: 2011-08-09

A Study in Adults With Type 2 Diabetes

CompletedNCT01421459

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2011-09-30End: 2012-09-30Updated: 2014-12-18

A Study in Adults With Type 1 Diabetes

CompletedNCT01421147

Eli Lilly and CompanyDiabetes Mellitus, Type 1

Start: 2011-08-31End: 2013-04-30Updated: 2014-10-09

Phase 4

Perioperative Insulin Glargine Dosing Study

CompletedNCT00309465

Tamra DukatzDiabetes, Surgery

Start: 2005-10-31End: 2009-10-31Updated: 2012-12-03

Related Papers

Impact of long-term glucose variability on coronary atherosclerosis progression in patients with type 2 diabetes: a 2.3 year follow-up study.

2020-09-2521 citations

Visit-to-visit fasting plasma glucose variability is an important risk factor for long-term changes in left cardiac structure and function in patients with type 2 diabetes.

2019-04-1629 citations

Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation.

2018-05-315 citations

Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study.

2018-03-145 citations

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01